PL2249821T3 - Zastosowanie estrów amidoksymowych kwasu karboksylowego i estrów nhydroksyguanidynowych kwasu karboksylowego do wytwarzania proleków - Google Patents

Zastosowanie estrów amidoksymowych kwasu karboksylowego i estrów nhydroksyguanidynowych kwasu karboksylowego do wytwarzania proleków

Info

Publication number
PL2249821T3
PL2249821T3 PL09705303T PL09705303T PL2249821T3 PL 2249821 T3 PL2249821 T3 PL 2249821T3 PL 09705303 T PL09705303 T PL 09705303T PL 09705303 T PL09705303 T PL 09705303T PL 2249821 T3 PL2249821 T3 PL 2249821T3
Authority
PL
Poland
Prior art keywords
carboxylic acid
acid esters
hydroxyguanidine
amidoxime
producing prodrugs
Prior art date
Application number
PL09705303T
Other languages
English (en)
Inventor
Bernd Clement
Christiane Reeh
Helen Hungeling
Original Assignee
Dritte Patentportfolio Beteili
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dritte Patentportfolio Beteili filed Critical Dritte Patentportfolio Beteili
Publication of PL2249821T3 publication Critical patent/PL2249821T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/62—Oximes having oxygen atoms of oxyimino groups esterified
    • C07C251/64—Oximes having oxygen atoms of oxyimino groups esterified by carboxylic acids
    • C07C251/66—Oximes having oxygen atoms of oxyimino groups esterified by carboxylic acids with the esterifying carboxyl groups bound to hydrogen atoms, to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL09705303T 2008-02-01 2009-02-02 Zastosowanie estrów amidoksymowych kwasu karboksylowego i estrów nhydroksyguanidynowych kwasu karboksylowego do wytwarzania proleków PL2249821T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008007381A DE102008007381A1 (de) 2008-02-01 2008-02-01 Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
PCT/EP2009/051132 WO2009095499A1 (de) 2008-02-01 2009-02-02 Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs
EP09705303.7A EP2249821B1 (de) 2008-02-01 2009-02-02 Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs

Publications (1)

Publication Number Publication Date
PL2249821T3 true PL2249821T3 (pl) 2015-12-31

Family

ID=40532565

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09705303T PL2249821T3 (pl) 2008-02-01 2009-02-02 Zastosowanie estrów amidoksymowych kwasu karboksylowego i estrów nhydroksyguanidynowych kwasu karboksylowego do wytwarzania proleków

Country Status (20)

Country Link
US (2) US20110028756A1 (pl)
EP (3) EP2732816A1 (pl)
JP (2) JP2011510956A (pl)
KR (1) KR20100110875A (pl)
CN (1) CN101951897B (pl)
AU (1) AU2009209560B2 (pl)
BR (1) BRPI0906569A2 (pl)
CA (1) CA2713784C (pl)
CY (1) CY1116801T1 (pl)
DE (1) DE102008007381A1 (pl)
DK (1) DK2249821T3 (pl)
ES (1) ES2547117T3 (pl)
HR (1) HRP20150961T1 (pl)
HU (1) HUE026276T2 (pl)
IL (1) IL207286A0 (pl)
PL (1) PL2249821T3 (pl)
PT (1) PT2249821E (pl)
SI (1) SI2249821T1 (pl)
WO (1) WO2009095499A1 (pl)
ZA (1) ZA201004767B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008007381A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
US9662308B2 (en) 2008-02-01 2017-05-30 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Orally bioavailable pentamidine prodrugs for the treatment of diseases
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
ES2611610T3 (es) * 2011-07-25 2017-05-09 Develco Pharma Schweiz Ag Ésteres de ácidos amidoxima-carboxílicos de dabigatrán como profármacos y su utilización como un medicamento
PT2550963T (pt) * 2011-07-25 2017-01-19 Dritte Patentportfolio Beteili Ésteres de ácido carboxílico de amidoxima de pentamidina como pró-drogas, e a utilização dos mesmos como fármaco
ES2416004B1 (es) * 2012-01-24 2014-01-28 Investigaciones Farmaceuticas Y Veterinarias, S.L. Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales.
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN104968340A (zh) * 2012-12-21 2015-10-07 沃利克斯制药股份有限公司 治疗肝脏疾病或病状的用途和方法
CN106831611B (zh) * 2017-01-23 2019-06-21 北京化工大学 一种偕胺肟类化合物及其在制备抑制癌细胞增殖药的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
JP2001031586A (ja) * 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
EP1294405A2 (en) 2000-06-14 2003-03-26 Corixa Corporation Prodrug compounds cleavable by thimet oligopeptidase
US6897034B2 (en) * 2001-06-11 2005-05-24 Medarex, Inc. CD10-activated prodrug compounds
JP2005509606A (ja) * 2001-10-03 2005-04-14 ファルマシア・コーポレーション 凝血カスケードを選択的に阻害するのに有用な置換された多環式化合物のプロドラッグ
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
JPWO2005049636A1 (ja) * 2003-11-21 2007-06-07 日本電気株式会社 タンパク質の分析方法
EP1767526B1 (en) * 2004-06-30 2012-10-24 Toyama Chemical Co., Ltd. Arylamidine derivative, salt thereof and antifungal containing these
DE102006034256A1 (de) * 2006-07-21 2008-01-31 Christian-Albrechts-Universität Zu Kiel Verbesserung der Bioverfügbarkeit von Wirkstoffen mit Amidinfunktion in Arzneimitteln
DE102008007381A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten

Also Published As

Publication number Publication date
PT2249821E (pt) 2015-10-13
HUE026276T2 (en) 2016-06-28
JP2016193927A (ja) 2016-11-17
KR20100110875A (ko) 2010-10-13
CN101951897A (zh) 2011-01-19
DK2249821T3 (en) 2015-10-05
EP2985021A1 (de) 2016-02-17
WO2009095499A1 (de) 2009-08-06
DE102008007381A1 (de) 2009-08-13
US20110028756A1 (en) 2011-02-03
AU2009209560B2 (en) 2013-10-31
CA2713784C (en) 2016-09-27
US20140350293A1 (en) 2014-11-27
CN101951897B (zh) 2016-01-20
CA2713784A1 (en) 2009-08-06
AU2009209560A1 (en) 2009-08-06
EP2249821A1 (de) 2010-11-17
CY1116801T1 (el) 2017-03-15
EP2732816A1 (de) 2014-05-21
SI2249821T1 (sl) 2015-12-31
HK1153144A1 (zh) 2012-03-23
ZA201004767B (en) 2011-04-28
EP2249821B1 (de) 2015-07-29
HRP20150961T1 (hr) 2015-11-06
BRPI0906569A2 (pt) 2015-07-07
IL207286A0 (en) 2010-12-30
US9353047B2 (en) 2016-05-31
JP2011510956A (ja) 2011-04-07
ES2547117T3 (es) 2015-10-01

Similar Documents

Publication Publication Date Title
IL207286A0 (en) Use of amidoxime carboxylic acid esters and n - hydroxyguanidine carboxylic acid esters for producing prodrugs
ZA201105612B (en) Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
PL2352497T3 (pl) Proces przygotowania estrów aminokwasowych delta-9-thc
PL2184270T3 (pl) Katalizowane zeolitem wytwarzanie związków alfa-hydroksykwasów karboksylowych i ich estrów
ZA201100528B (en) Method for the synthesis of bioresourced acrylic acid esters
BRPI1012744A2 (pt) "processo contínuo para preparação de ésteres de ácidos carboxílicos alifáticos"
SG10201402443PA (en) Isoxazolines As Inhibitors Of Fatty Acid Amide Hydrolase
ZA201103085B (en) Method for the synthesis of an omega-amino acid or ester starting from a monounsaturated fatty acid or ester
ZA201206168B (en) A process for the enzymatic synthesis of fatty acid alkyl esters
PT2743270T (pt) Dicianopiridinas substituídas por alquilamina e seus profármacos de ésteres de aminoácidos
IL224955A (en) Morphic forms of phosphonic acid esters and methods for their synthesis
EP2325166A4 (en) METHOD FOR INHIBITING THE POLYMERIZATION OF AN ISOCYANATE-GROUP-CONTAINING ETHYLENE DISCOVERY CARBOXYLIC ACID ESTER COMPOUND, AND METHOD FOR PRODUCING AN ETHYLENE-UNSATURATED CARBOXYLIC ACID ESTER COMPOUND CONTAINING AN ISOCYANATE GROUP
PT2358851E (pt) Utilização de ácido metanossulfónico para a preparação de ésteres de ácidos gordos
LT2550963T (lt) Pentamidino-amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų naudojimas kaip vaistų
LT2550966T (lt) Dabigatrano amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų panaudojimas kaip vaistų
IL215870A0 (en) Processes for purification of 1-methylpyrzole-4-carboxylic acid esters
IL201584A0 (en) Process for the preparation of pure acrylate esters
ZA201107378B (en) Process for the preparation of a biphenyl-2ylcarbamic acid ester
AP2831A (en) Production of fatty acid and fatty acid ester
IL230860A0 (en) A process for the production of an acidic cyclopropenecarboxylic ester compound
PL388460A1 (pl) Nowe estry kwasu borowego oraz nowy sposób otrzymywania estrów kwasu borowego
HU0800437D0 (en) Continuous process for producing fatty acid alkyl esters
ZA201001854B (en) Production of fatty acid and fatty acid ester